Abstract:BackgroundOvarian cancer is one of the major causes of death in women worldwide. Despite improvements in conventional treatment approaches, such as surgery and chemotherapy, a majority of patients with advanced ovarian cancer experience relapse and eventually succumb to the disease; the outcome of patients remains poor. Hence, new therapeutic strategies are urgently required. The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) is activated in approximately 70 % of ovarian cancers, resulting in hyperactive signaling cascades that relate to cellular growth, proliferation, survival, metabolism, and angiogenesis. Consistent with this, a number of clinical studies are focusing on PI3K pathway as an attractive target in the treatment of ovarian cancer. In this review, we present an overview of PI3K pathway as well as its pathological aberrations reported in ovarian cancer. We also discuss inhibitors of PI3K pathway that are currently under clinical investigations and the challenges these inhibitors face in future clinical utility.MethodsPubMed was searched for articles of relevance to ovarian cancer and the PI3K pathway. In addition, the ClinicalTrials.gov was also scanned for data on novel therapeutic inhibitors targeting the PI3K pathway.ResultsGenetic aberrations at different levels of PI3K pathway are frequently observed in ovarian cancer, resulting in hyperactivation of this pathway. The alterations of this pathway make the PI3K pathway an attractive therapeutic target in ovarian cancer. Currently, several inhibitors of PI3K pathway, such as PI3K/AKT inhibitors, rapamycin analogs for mTOR inhibition, and dual PI3K/mTOR inhibitors are in clinical testing in patients with ovarian cancer.ConclusionsPI3K pathway inhibitors have shown great promise in the treatment of ovarian cancer. However, further researches on selection patients that respond to PI3K inhibitors and exploration of effective combinatorial therapies are required to improve the management of ovarian cancer.

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Targeting the PI3K pathway in cancer: are we making headway?

Targeting PI3K/Akt signal transduction for cancer therapy

A bibliometric analysis of the application of the PI3K-AKT-mTOR signaling pathway in cancer

Targeting PI3K in cancer: mechanisms and advances in clinical trials

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer

PI3K/AKT signaling pathway and cancer: an updated review

The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review

Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?

PI3K Inhibitors for Cancer Therapy: What Has Been Achieved So Far?

The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions

Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer

PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer

Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?

The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non‐coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles